AstraDx: Sub-Hour AST Via Computational Image Processing
AstraDx:通过计算图像处理实现不到一小时的 AST
基本信息
- 批准号:10547198
- 负责人:
- 金额:$ 29.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acinetobacter baumanniiAddressAgreementAmericanAntibioticsAntimicrobial ResistanceAntimicrobial susceptibilityAreaBacteriaBehaviorBiotechnologyBloodBostonCaringCategoriesCenters for Disease Control and Prevention (U.S.)Cessation of lifeCodeCommunicable DiseasesComplexDangerousnessDataData SetDetectionDevicesDiseaseDrug CombinationsESKAPE pathogensEngineeringEnsureEnterococcusEyeFosteringGenus staphylococcusGoalsGoldGrowthGuidelinesHealthHomeHospitalsHourHumanImageIncubatorsInfectionIntelligenceLeadLegal patentLifeMeasuresMechanicsMethodsMicrobiologyMinimum Inhibitory Concentration measurementMissionModernizationMorbidity - disease rateOpticsOrganismOutcomePatientsPerformancePharmaceutical PreparationsPhasePhenotypeProcessPseudomonas aeruginosaPublic HealthResistanceResolutionResourcesRunningScientistSepsisSideSmall Business Innovation Research GrantSumTechnologyTestingTimeTrainingUnited States National Institutes of HealthValidationVancomycin resistant enterococcusWorkbiosafety level 2 facilitycarbapenem resistancecomputational pipelinescostdisease diagnosticdrug standardexperimental studyimage processingimprovedinnovationmembermethicillin resistant Staphylococcus aureusmortalitymortality riskmultidrug-resistant Pseudomonas aeruginosanormal microbiotaoptical imagingpathogenpersonalized diagnosticspreventpriority pathogenroutine Bacterial stainserial imaging
项目摘要
PROJECT SUMMARY/ABSTRACT
Antimicrobial susceptibility testing (AST) for bacterial bloodstream infections (BSIs) is dangerously slow.
Starting from a positive blood culture, AST currently takes a median of 15 hours, and often takes days. Until
results are available, there is no choice but to treat patients with empiric antibiotics and hope the pathogen is
susceptible. This is unacceptable. BSIs are serious, rapidly fatal infections that kill a quarter-million Americans
each year, including a third of all hospital deaths. Empiric antibiotics destroy patients’ normal flora,
predisposing them to additional, untreatable infections. Every hour a patient is on the wrong antibiotic
increases risk of death by 7.6%. This key problem has made rapid, affordable AST a global priority.
To address this problem, AstraDx has developed a low-cost new AST device that we hypothesize can perform
AST in under an hour. The purpose of this proposal is to test this hypothesis. Preliminary studies involving
multiple experiments on 19 strains vs. 8 standard antibiotics have demonstrated growth detection in 31±18
minutes (95% range, 20-63 minutes). Strains tested included methicillin-resistant S. aureus (MRSA),
vancomycin-resistant Enterococci (VRE), carbapenem-resistant A. baumannii (CRAB), carbapenem-resistant
Enterobacterales (CRE), multidrug-resistant P. aeruginosa—all high priority per the CDC—as well as
corresponding susceptible strains. The innovation that makes these results possible is a new computational
image-processing pipeline, which enables extremely sensitive and robust detection of an antibiotic’s effect on
growth, often in less than the strain’s doubling time. A second innovation is the use of inexpensive standard
components, leading to an affordable device and consumables. These innovations support our long-term goal
of making rapid AST universally available. We will test our hypothesis through three tightly focused specific
aims. Aim 1 will generate training data on diverse bug-drug combinations, with bacteria from simulated-
positive blood cultures grown in the presence of doubling dilutions of antibiotic on 384-well plates, similar to the
current phenotypic gold standard, with multiple antibiotics on each plate. Aim 2 will use the images from Aim 1
to create a unified picture of each strain’s behavior in the presence of each antibiotic, which we will use to
refine how we determine minimum inhibitory concentrations (MICs) in order to maximize categorical agreement
with the CLSI gold standard. Finally, Aim 3 will validate the method from Aim 2 by testing additional bacterial
strains and measuring categorical agreement with the gold standard, per FDA standard guidelines.
The expected outcome is a device proven to achieve sub-hour AST with FDA-level performance on a wide
variety of pathogens, establishing technical merit, feasibility, and commercial potential for an SBIR Phase II.
Our advanced technology, a clearly identified product, will help meet the critical need for rapid, highly sensitive
infectious-disease diagnostics to address antimicrobial resistance for life-threatening BSIs and sepsis.
项目总结/摘要
细菌性血流感染(BSI)的抗菌药物敏感性测试(AST)非常缓慢。
从阳性血培养开始,AST目前平均需要15小时,通常需要几天。直到
结果可用,别无选择,只能使用经验性抗生素治疗患者,并希望病原体
易受影响这是不可接受的。BSIs是严重的,迅速致命的感染,导致25万美国人死亡
包括三分之一的医院死亡。经验性抗生素会破坏患者正常的植物群,
使他们容易受到额外的无法治愈的感染。每小时就有一个病人用错抗生素
死亡风险增加7.6%。这一关键问题使快速、可负担得起的AST成为全球优先事项。
为了解决这个问题,AstraDx开发了一种低成本的新型AST设备,我们假设它可以执行
一个小时内。本提案的目的是检验这一假设。初步研究涉及
对19种菌株与8种标准抗生素进行的多项实验表明,在31±18
分钟(95%范围,20-63分钟)。检测的菌株包括耐甲氧西林的S.金黄色葡萄球菌(MRSA),
万古霉素耐药肠球菌(VRE)、碳青霉烯类耐药A.鲍曼不动杆菌(CRAB),碳青霉烯类耐药
肠球菌(CRE)、耐多药铜绿假单胞菌-根据CDC,所有这些都是高度优先的-以及
相应的敏感菌株。使这些结果成为可能的创新是一种新的计算方法,
图像处理流水线,能够非常灵敏和强大地检测抗生素对
生长,往往在不到应变的倍增时间。第二个创新是使用廉价的标准
组件,从而产生负担得起的设备和消耗品。这些创新支持我们的长期目标
使快速AST普遍可用。我们将通过三个密切关注的具体问题来验证我们的假设。
目标。Aim 1将生成关于不同细菌-药物组合的训练数据,其中细菌来自模拟-
阳性血培养物在抗生素加倍稀释的情况下在384孔板上生长,类似于
目前的表型金标准,每个平板上有多种抗生素。Aim 2将使用Aim 1中的图像
创建一个统一的图片,每个菌株的行为在每种抗生素的存在,我们将使用,
完善我们如何确定最低抑菌浓度(MIC),以最大限度地提高分类一致性
CLSI黄金标准最后,目标3将通过检测其他细菌来验证目标2中的方法
根据FDA标准指南,菌株和测量与金标准的分类一致性。
预期的结果是一个设备被证明可以实现亚小时AST与FDA级的性能在广泛的
各种病原体,建立技术优点,可行性和商业潜力的SBIR第二阶段。
我们先进的技术,一个明确的产品,将有助于满足快速,高灵敏度的关键需求
感染性疾病诊断,以解决危及生命的BSI和败血症的抗菌素耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan Florez其他文献
Jonathan Florez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan Florez', 18)}}的其他基金
AstraDx: Sub-Hour AST Via Computational Image Processing
AstraDx:通过计算图像处理实现不到一小时的 AST
- 批准号:
10670875 - 财政年份:2022
- 资助金额:
$ 29.96万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant